- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02259881
Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers
October 7, 2014 updated by: Boehringer Ingelheim
Investigation of the Effect of 0.9, 2.25 or 4.5 mg of BIBT 986 Over 1 Hour, Followed by 0.2, 0.5 or 1.0 mg/Hour of BIBT 986 for 7 Hours Given as IV Infusion on Tissue Factor Triggered Coagulation in a Randomised, Placebo Controlled, Dose Escalation Design in Healthy Male Volunteers
To compare with placebo the anticoagulant activity of three dosages of BIBT 986 on parameters of coagulation, platelet activation and inflammation in a model of tissue factor triggered activation of the coagulation system; to examine the safety of BIBT 986 in this setting
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects as determined by the screening procedure
- Signed written informed consent form in accordance with good clinical practice (GCP) and local legislation was available
- Age ≥ 18 and ≤ 40 years
- Body mass index: BMI ≥ 18 and ≤ 29.9 kg/m2
- Normal findings in medical history and physical examination unless the investigator considered an abnormality to be clinically irrelevant
- Normal laboratory parameters unless the investigator considered an abnormality to be clinically irrelevant
Exclusion Criteria:
- Any finding in the medical examination (including blood pressure, pulse rate, ECG, and laboratory parameters) deviating from normal and of clinical relevance
- History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, autoimmune, hormonal disorders, diseases of the central nervous system (such as epilepsy), or psychiatric disorders
- Symptoms of a clinically relevant illness in the 3 weeks before the first trial day
- History of orthostatic hypotension, fainting spells, and blackouts
- Chronic or relevant acute infections
- History of allergy / hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator
History of
- any bleeding disorder including prolonged or habitual bleeding
- any familial bleeding disorder
- other haematological disease
- cerebral bleeding (e.g. after a car accident)
- commotio cerebri
- Hereditary deficiency of protein C or S, or a mutation of factor V (Leiden), or any other known abnormality affecting coagulation, fibrinolysis, or platelet function
- Platelet count < 150000/μL
- Any ECG value outside of the reference range of clinical relevance (QRS interval > 110 ms or QTcB (QT interval Bazett correction) > 450 ms will be an obligatory exclusion criterion)
- Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
- Use of any drugs that might influence the results of the trial within 10 days prior to administration or during the trial
- Participation in another trial with an investigational drug within 2 months prior to administration or during trial
- Participation in an LPS trial within the last six weeks
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
- Concurrent or history of drug, alcohol, tobacco or coffee / tea / cola abuse
- Blood donation within 1 month prior to administration or during the trial
- Excessive physical activities within 5 days prior to administration or during the trial
- Seropositivity for hepatitis B surface antigen (HBs-Ag), hepatitis C virus (HCV), HIV 1, or HIV 2 antibodies
- Weight over 95 kg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Endotoxin derived from E. coli bacteria, used for activation of coagulation
|
Experimental: Low dose of BIBT 986 CL
|
Endotoxin derived from E. coli bacteria, used for activation of coagulation
|
Experimental: Medium dose of BIBT 986 CL
|
Endotoxin derived from E. coli bacteria, used for activation of coagulation
|
Experimental: High dose of BIBT 986 CL
|
Endotoxin derived from E. coli bacteria, used for activation of coagulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in activated partial thromboplastin time (aPTT)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in international normalized ratio (INR)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in thrombin time (TT)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in ecarin clotting time (ECT)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in prothrombin fragment (F1+2)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in D-dimer
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in thrombin anti-thrombin complexes (TAT)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in protein C activity
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in antithrombin
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in thrombomodulin
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in tissue factor messenger RNA (mRNA)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in platelet count
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in plasmin antiplasmin complexes (PAP)
Time Frame: Pre-dose, up to day 14 after start of treatment
|
Pre-dose, up to day 14 after start of treatment
|
|
Change in soluble P-selectin
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in tumor necrosis factor alpha (TNF alpha)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in interleukin-6 (IL-6)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in primary haemostasis measured by closure times
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Number of subjects with clinically relevant changes in vital signs
Time Frame: up to 14 days after start of treatment
|
blood pressure, pulse rate, body temperature
|
up to 14 days after start of treatment
|
Number of subjects with clinically relevant changes in laboratory parameters
Time Frame: up to 14 days after start of treatment
|
up to 14 days after start of treatment
|
|
Number of subjects with adverse events
Time Frame: up to 14 days after start of treatment
|
up to 14 days after start of treatment
|
|
Number of subjects with clinically relevant changes in ECG
Time Frame: up to 14 days after start of treatment
|
up to 14 days after start of treatment
|
|
Change in thrombus precursor protein
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
|
Change in soluble E-selectin
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration-time curve (AUC)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Maximum concentration in plasma at the end of the infusion (Cgh)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Apparent terminal half-life of BIBT 986 in plasma (t1/2)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Mean residence time of BIBT 986 in the body after intravenous bolus administration (MRT)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Volume of distribution of BIBT 986 in plasma at steady state (Vss)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Apparent volume of distribution of BIBT 986 during the terminal phase after intravenous infusion (Vz)
Time Frame: up to 48 hours after start of treatment
|
up to 48 hours after start of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Primary Completion (Actual)
May 1, 2003
Study Registration Dates
First Submitted
October 7, 2014
First Submitted That Met QC Criteria
October 7, 2014
First Posted (Estimate)
October 9, 2014
Study Record Updates
Last Update Posted (Estimate)
October 9, 2014
Last Update Submitted That Met QC Criteria
October 7, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1192.11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States